溶瘤HSV G47δ联合血管生成抑制因子、丝裂霉素C抗膀胱癌效应研究
|
摘要
研究表明,第三代溶瘤单纯疱疹病毒G47δ(Herpes simplex Virus G47delta,简称G47δ),具有较第二代溶瘤单纯疱疹病毒G207特异性地杀伤肿瘤细胞的能力更强、速度更快。内源性血管生长抑制因子可抑制肿瘤原发灶和转移灶的生长,具有无免疫源性,不良反应轻等优点。丝裂霉素C(Mitomycin C,MMC)广泛用于膀胱尿路上皮癌(简称膀胱癌)术后的膀胱灌注化疗。联合应用G47δ与内源性血管生长抑制因子或MMC抗膀胱癌,可能发挥协同作用。
研究目的
1.探讨能否从人膀胱癌组织克隆出Kringle 5基因(简称K5),并鉴定其原核表达蛋白有无生物学活性。
2.探讨G47δ、pcDNA3.1/K5对膀胱癌细胞的增殖抑制作用,二者联合应用有无协同作用。
3.探讨联合应用G47δ和MMC对膀胱癌细胞的协同杀伤作用。
4.探讨能否从人膀胱癌组织克隆出Endostatin基因(简称ES),并把ES与K5拼接构建成融合基因的技术和方法。
5.探讨膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的表达水平与膀胱癌分级、分期的相关性,为运用内源性血管生成抑制因子抗膀胱癌治疗提供依据。
研究内容与方法
1.K5基因的克隆、优化表达、纯化及活性鉴定:从人膀胱癌组织中提取总RNA,RT-PCR扩增K5基因;构建原核表达载体pGEX-5X-1/K5;运用工程菌表达蛋白,并对表达条件参数进行优化;带谷胱甘肽巯基转移酶(GST)标签琼脂糖4B亲和柱层析、纯化蛋白;CellTiter 96 AQ_(ueous)细胞增殖检测法(MTS)检测K5蛋白对人脐静脉内皮细胞ECV304增殖的影响。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:提取病毒DNA,PCR扩增目的片段,进行琼脂糖凝胶电泳和基因测序鉴定G47δ构建的正确性;蚀斑实验测定G47δ的蚀斑形成单位;培养人膀胱癌细胞株BIU-87(浅表性膀胱癌)和EJ(侵润性膀胱癌)细胞;构建重组真核表达质粒pcDNA3.1/K5,用脂质体PolyFect介导pcDNA3.1/K5转染BIU-87和EJ细胞,再用G47δ感染癌细胞,MTS法检测癌细胞增殖情况;构建pEGFP-n2/K5,用PolyFect介导pEGFP-n2/K5转染癌细胞,再用G47δ感染癌细胞,荧光显微镜观测K5在癌细胞中的定位变化;蚀斑实验检测pcDNA3.1/K5-PolyFect对G47δ的繁殖影响;pcDNA3.1/K5转染癌细胞后,RT-PCR检测癌细胞内K5 mRNA水平。
3.G47δ联合MMC抗膀胱癌效应研究:G47δ感染癌细胞1h后,加MMC,MTS法检测癌细胞增殖情况,Chou-Talalay法推算联合用药指数并用Isobologram法分析联合用药效应;比较G47δ与野生型HSV-1对癌细胞增殖抑制作用;蚀斑实验检测MMC对G47δ病毒繁殖有无影响。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:从人膀胱癌组织中提取总RNA,RT-PCR扩增ES基因;重叠延伸拼接法(SOE)构建ES-K5融合基因;构建真核表达质粒pcDNA3.1/ES、pcDNA3.1/ES-K5、pEGFP-n2/ES-K5,基因测序鉴定。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:酶联免疫吸附试验(ELISA)检测膀胱癌患者血清、尿液中VEGF(vascularendothelial growth factor)、Angiostatin(AS)、ES、K5表达水平,免疫组织化学法(IHC)检测膀胱癌组织标本中VEGF、AS、ES、K5表达情况,分析它们与膀胱癌分级、分期的相关性。
实验结果
1.K5基因的克隆、优化表达、纯化及活性鉴定:PCR扩增得到282 bp基因片段,并成功插入pGEX-5X-1质粒;诱导温度为37℃,IPTG浓度为1mmol/L,时间为6h,pGEX-5X-1/K5在BL21中表达最佳;获得特异性融合蛋白,经凝血酶酶切后得到分子量约为12kD的重组K5蛋白(rK5);rK5能特异性抑制ECV304细胞增殖,抑制率最高蛋白浓度为5μg/ml。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:G47δ能在Vero细胞中繁殖,并出现特征性的CPE病变;琼脂糖凝胶电泳PCR扩增的G47δ目的片段条带宽亮,位于250bp、500bp之间,而PCR扩增的HSV-1目的片段位于500bp、750bp之间,病毒DNA序列测序均正确,表明所重组G47δ构建正确;蚀斑实验计算G47δ蚀斑形成单位为2.5×10~7pfu/ml;pcDNA3.1/K5、G47δ对BIU-87、EJ细胞增殖有抑制作用,而且抑制率与G47δ剂量、作用时间正相关,联合作用抑制率比其单一作用要强;荧光显微镜观测,K5-EGFP融合蛋白在癌细胞胞浆、胞核中均有表达,G47δ对其定位并无影响;pcDNA3.1/K5对G47δ繁殖无明显影响,蚀斑形成单位数基本相同;pcDNA3.1/K5转染癌细胞后,RT-PCR扩增K5 mRNA条带位于250bp、500bp之间,符合K5核苷酸大小。
3.G47δ联合MMC抗膀胱癌效应研究:G47δ、MMC对BIU-87、EJ细胞增殖均有抑制作用,而且抑制率与G47δ、MMC的剂量和作用时间正相关,Chou-Talalay法分析合用指数CI_x＜1,Isobologram法分析q＜1,表明二者具有协同作用;G47δ对癌细胞的增殖抑制作用比野生型HSV-1明显要强;MMC对G47δ繁殖无明显影响,蚀斑形成单位数基本相同。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:PCR扩增得到552bp基因片段,并成功插入pcDNA3.1质粒,基因测序正确;SOE法所构建融合基因ES与K5中间的Linker为(Gly4Ser)3,ES-K5融合基因成功插入pcDNA3.1和pEGFP-n2真核表达质粒,基因测序正确。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:膀胱癌患者血清、尿液中VEGF、AS、ES、K5表达水平与膀胱癌分级、分期正相关;VEGF、AS、ES在癌组织中的表达也与分期正相关。
结论
1.K5基因的克隆、优化表达、纯化及活性鉴定:
1)从膀胱癌组织能克隆出Kringle5基因。
2)对蛋白表达条件参数优化后,确定诱导温度为37℃,IPTG浓度为1mmol/L,时间为6h,pGEX-5X-1/K5在BL21中表达最佳。
3)含重组质粒pGEX-5X-1/K5大肠杆菌表达产物量较多且易纯化。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:
1) pcDNA3.1/K5、G47δ对膀胱癌细胞增殖均有抑制作用,而且抑制率与G47δ剂量、作用时间正相关,pcDNA3.1/K5与G47δ联合作用抑制率比其单一作用要强。
2) pcDNh3.1/K5对G47δ病毒繁殖无明显影响。
3) pcDNA3.1/K5转染癌细胞后,能在细胞内稳定表达。
3.G47δ联合MMC抗膀胱癌效应研究:
1) G47δ、MMC对膀胱癌细胞增殖均有抑制作用,抑制率与G47δ、MMC的剂量和作用时间正相关,二者合用具有协同作用。
2) G47δ对癌细胞的增殖抑制作用比野生型HSV-1明显要强。
3) MMC对G47δ繁殖无明显影响。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:
1)从膀胱癌组织能克隆出Endostatin基因。
2) SOE法所构建Linker能把ES与K5拼接起来,并能成功插入到真核表达质粒中。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:
1) VEGF、AS、ES、K5在膀胱癌中分泌表达与分级、分期正相关。
2)肿瘤血管新生正性和负性调控平衡被打破的原因可能是由于血管生成因子与血管生成抑制因子表达分泌均增多、增强,但以前者更为显著。
3)去除原发肿瘤后微转移灶迅速生长的原因是由于微转移灶中血管生成因子与由原发肿瘤所分泌的血管生成抑制因子来源减少而使调控平衡被打破,但这一机制不能合理解释血管生成抑制因子表达量与肿瘤分级、分期正相关的现象,有待于进一步研究。
The third-generation oncolytic herpes simplex virus G47δ(G47δ) can kill cancer cells more stronger and faster than the second-generation oncolytic HSV G207,it has already been proved by results of experimental research.The growth of primary and metastatic cancers can be restrained by endogenous angiogenesis inhibitors with merits of little immunogenicity or adverse reactions.Mitomycin C(MMC) as an intravesical chemotherapy drug is widely used to treat urothelial carcinoma of bladder after transurethral resection of bladder tumor(TURBt).It is possible to exert drug synergism to combine oncolytic herpes simplex virus G47δwith angiogenesis inhibitor or MMC on urothelial carcinoma of bladder.
Objective
1.To investigate whether the Kringle 5(K5) gene could be cloned from the human bladder carcinoma tissue,and to identify biological activity of bacterial expressed recombinant K5 protein.
2.To investigate the killing effect of G47δor pcDNA3.1/K5 on bladder cancer cells,and to evaluate the drug synergism of the combination of the two drugs.
3.To investigate the drug synergism of G47δand MMC on killing bladder cancer cells.
4.To investigate whether the Endostatin(ES) gene could be cloned from the human bladder carcinoma tissue,and the method of ES fused with K5 gene.
5.To investigate the correlation of pathologic grade and clinical stage with expression level of VEGF(vascular endothelial growth factor),Angiostatin(AS), ES,K5 in serum,urine,or cancer tissue.
Materials and Methods
1.Cloning,optimal expression,purification and activity identification of K 5: Total RNA was extracted from human bladder carcinoma tissue,then the K5 cDNA was amplified by RT-PCR.A recombinant prokaryotic expression vector pGEX-5X-1/K5 was constructed and the K5 protein was expressed in engineering bacteria.K5 was purified by tagged GST agarose 4B affinity column chromatography,the anti-proliferative effects of K5 on ECV304 were examined by MTS assay.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:DNA were extracted from G47δand wild-type HSV-1,then the target fragments amplified by PCR were identified by agarose gel electrophoresis and gene sequencing technologies; Virus titer was determined by virus plaque test;A eukaryotic expression vector pcDNA3.1/K5 was constructed and pcDNA3.1/K5 was transferred into human urinary bladder carcinoma cell line BIU-87 or EJ by polyfect liposome,subsequently,the cells were infected with G47δ,then the anti-proliferative effects of pcDNA3.1/K5 and G47δon BIU-87 or EJ cell were examined by MTS assay;Recombinant plasmid of pEGFP-n2/K5 was constructed and the plasmid was transferred into cancer cells,and the cells were infected with G47δsubsequently,the location of K5 in cells was observed through fluorescence microscope;The effects of pcDNA3.1/K5 on replication of G47δwas assessed using virus plaque test;K5 mRNA was detected by RT-PCR after pcDNA3.1/K5 was transferred into cancer cells by PolyFect liposome.
3.Combining MMC with G47δon killing bladder cancer cells:The cancer cells were infected with G47δ,1h later,MMC was added,the anti-proliferative effects of MMC and G47δon BIU-87 or EJ cells were examined by MTS assay,the combination index (CI)-isobologram of Chou-Talalay analysis was used to analyze virus and drug combinations;The anti-proliferative effects of wild-type HSV-1 and G47δon cancer cell were assessed by MTS assay;The effects of MMC on replication of G47δwas assessed using virus plaque test.
4.Cloning of ES,ES fused with K5 gene and eukaryotic expression vector with ES-K5 was constructed:Total RNA was extracted from human bladder carcinoma tissue,then the ES cDNA was amplified by RT-PCR;The fusion gene of ES-K5 was artificially synthesized by splicing by overlap extension(SOE) method and inserted into eukaryotic expression vectors such as pcDNA3.1,pEGFP-n2,then the recombinant plasmids were identified by gene sequencing technologies.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:Expression level of VEGF,AS,ES,K5 in serum and urine were detected with ELISA,and expression level of them in cancer tissue was detected with IHC,then correlation of pathologic grade and clinical stage with the expression level of VEGF,AS, ES,K5 was analyzed.
Results
1.Cloning,optimal expression,purification and activity identification of K 5: The acquired gene was 282bp,and it was inserted into pGEX-5X-1 plasmid successfully; The optimal parameters of expressing K5 in prokaryotie expression system pGEX-5X-1 are: engineering bacteria for E.coli BL21,temperature for 37℃,concentration of IPTG for 1 mmol/L,time for 6h;K5 protein,molecular weight of 12 kD,was obtained after digested by thrombin;K5 protein showed effective in specifically inhibiting proliferation of ECV304 and its optimum concentration was 5μg/ml.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:G47δvirus can incubate very rapidly in Vero cell;Agarose electrophoresis shows:the target fragment of G47δamplified by PCR was between 250bp and 500bp,but the target fragment of wild-type HSV-1 was between 500bp and 750bp,DNA sequences of two viruses were right by gene sequencing analysis,these indicated that the recombinant virus of G47δwas constructed successfully;The virus titer was 2.5×10~7 pfu/ml by virus plaque test;Both pcDNA3.1/K5 and G47δcould restrain the proliferation of BIU-87 and EJ cells, the inhibition effects were positively correlated with their action time and dosage,and combining pcDNA3.1/K5 with G47δcould cause the greater inhibition than one of them; G47δdid not disturb the location of K5 in cytoplasm and karyon;pcDNA3.1/K5 hardly disturbed on replication of G47δ,the number of plaque forming unit was same;K5 mRNA was between 250bp and 500bp,which was accorded with the molecular weight of K5.
3.Combining MMC with G47δon killing bladder cancer cells:Both MMC and G47δcould restrain the proliferation of BIU-87 and EJ cells,the inhibition effects were positively correlated with their action time and dosage,and combination index<1 which indicated the drug synergism;G47δcaused the greater inhibition than wild-type HSV-1; MMC hardly disturbed on replication of G47δ,the number of plaque forming unit was same.
4.Cloning of ES,ES fused with K5 gene and eukaryotie expression vector with ES-K5 was constructed:The acquired gene was 552bp,and it was inserted into pcDNA3.1 plasmid successfully;The fusion gene of ES-K5 was constructed successfully by the method of SOE,the linker was(Gly4Ser)3,and ES-K5 was inserted into pcDNA3.1 and pEGFP-n2 plasmids successfully.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:Expression level of VEGF,AS,ES,K5 in serum and urine were positively correlated with pathologic grade and clinical stage;expression level of them in cancer tissue was positively correlated with pathologic grade too.
Conclusions
1.Cloning,optimal expression,purification and activity identification of K5:
1) K5 gene was cloned successfully from human bladder carcinoma tissue.
2) The optimal parameters of expressing K5 in prokaryotic expression system pGEX-5X-1 are:engineering bacteria for E.coli BL21,temperature for 37℃, concentration of IPTG for 1 mmol/L,time for 6h.
3) K5 protein has a large expression level and easy to purify by way of E.coli containing recombinant plasmid pGEX-5X-1/K5.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:
1) pcDNA3.1/K5 and G47δcould restrain the proliferation of bladder cancer cell,the inhibition effects were positively correlated with their action time and dosage,and combining pcDNA3.1/K5 with G47δcaused the greater inhibition than one of them.
2) pcDNA3.1/K5 hardly disturbed on replication of G47δ.
3) pcDNA3.1/K5 can stably express in cells
3.Combining MMC with G47δon killing bladder cancer cells:
1) MMC and G47δcould restrain the proliferation of bladder cancer cells,the inhibition effects were positively correlated with their action time and dosage,and combination can produce synergistc effect.
2) G47δcaused greater inhibition than HSV-1.
3) MMC hardly disturbed on replication of G47δ.
4.Cloning of ES,ES fused with K5 gene and eukaryotic expression vector with ES-K5 was constructed:
1) ES gene was cloned successfully from human bladder carcinoma tissue.
2) Fusion gene of ES-K5 could be inserted into eukaryotic expression vectors.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:
1) Expression level of VEGF,AS,ES,K5 in bladder cancer was positively correlated with pathologic grade and clinical stage.
2) Positive and negative regulation control angiogenesis,and the balance is broken in tumor angiogenesis,the possible reason was that it increased the expression and secretion of both angiogenesis factors and angiogenesis inhibitors,but biological activity of angiogenesis factors is stronger.
3) The reason of a rapid progression of metastasis after surgical resection of the primary tumor is that the reduction of production and secretion of antimitotic factors by the cells of the primary tumor that inhibit the proliferation of metastatic cells,but it can not reasonably explain that expression level of angiogenesis inhibitor were positively correlated with pathologic grade and clinical stage.
研究目的
1.探讨能否从人膀胱癌组织克隆出Kringle 5基因(简称K5),并鉴定其原核表达蛋白有无生物学活性。
2.探讨G47δ、pcDNA3.1/K5对膀胱癌细胞的增殖抑制作用,二者联合应用有无协同作用。
3.探讨联合应用G47δ和MMC对膀胱癌细胞的协同杀伤作用。
4.探讨能否从人膀胱癌组织克隆出Endostatin基因(简称ES),并把ES与K5拼接构建成融合基因的技术和方法。
5.探讨膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的表达水平与膀胱癌分级、分期的相关性,为运用内源性血管生成抑制因子抗膀胱癌治疗提供依据。
研究内容与方法
1.K5基因的克隆、优化表达、纯化及活性鉴定:从人膀胱癌组织中提取总RNA,RT-PCR扩增K5基因;构建原核表达载体pGEX-5X-1/K5;运用工程菌表达蛋白,并对表达条件参数进行优化;带谷胱甘肽巯基转移酶(GST)标签琼脂糖4B亲和柱层析、纯化蛋白;CellTiter 96 AQ_(ueous)细胞增殖检测法(MTS)检测K5蛋白对人脐静脉内皮细胞ECV304增殖的影响。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:提取病毒DNA,PCR扩增目的片段,进行琼脂糖凝胶电泳和基因测序鉴定G47δ构建的正确性;蚀斑实验测定G47δ的蚀斑形成单位;培养人膀胱癌细胞株BIU-87(浅表性膀胱癌)和EJ(侵润性膀胱癌)细胞;构建重组真核表达质粒pcDNA3.1/K5,用脂质体PolyFect介导pcDNA3.1/K5转染BIU-87和EJ细胞,再用G47δ感染癌细胞,MTS法检测癌细胞增殖情况;构建pEGFP-n2/K5,用PolyFect介导pEGFP-n2/K5转染癌细胞,再用G47δ感染癌细胞,荧光显微镜观测K5在癌细胞中的定位变化;蚀斑实验检测pcDNA3.1/K5-PolyFect对G47δ的繁殖影响;pcDNA3.1/K5转染癌细胞后,RT-PCR检测癌细胞内K5 mRNA水平。
3.G47δ联合MMC抗膀胱癌效应研究:G47δ感染癌细胞1h后,加MMC,MTS法检测癌细胞增殖情况,Chou-Talalay法推算联合用药指数并用Isobologram法分析联合用药效应;比较G47δ与野生型HSV-1对癌细胞增殖抑制作用;蚀斑实验检测MMC对G47δ病毒繁殖有无影响。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:从人膀胱癌组织中提取总RNA,RT-PCR扩增ES基因;重叠延伸拼接法(SOE)构建ES-K5融合基因;构建真核表达质粒pcDNA3.1/ES、pcDNA3.1/ES-K5、pEGFP-n2/ES-K5,基因测序鉴定。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:酶联免疫吸附试验(ELISA)检测膀胱癌患者血清、尿液中VEGF(vascularendothelial growth factor)、Angiostatin(AS)、ES、K5表达水平,免疫组织化学法(IHC)检测膀胱癌组织标本中VEGF、AS、ES、K5表达情况,分析它们与膀胱癌分级、分期的相关性。
实验结果
1.K5基因的克隆、优化表达、纯化及活性鉴定:PCR扩增得到282 bp基因片段,并成功插入pGEX-5X-1质粒;诱导温度为37℃,IPTG浓度为1mmol/L,时间为6h,pGEX-5X-1/K5在BL21中表达最佳;获得特异性融合蛋白,经凝血酶酶切后得到分子量约为12kD的重组K5蛋白(rK5);rK5能特异性抑制ECV304细胞增殖,抑制率最高蛋白浓度为5μg/ml。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:G47δ能在Vero细胞中繁殖,并出现特征性的CPE病变;琼脂糖凝胶电泳PCR扩增的G47δ目的片段条带宽亮,位于250bp、500bp之间,而PCR扩增的HSV-1目的片段位于500bp、750bp之间,病毒DNA序列测序均正确,表明所重组G47δ构建正确;蚀斑实验计算G47δ蚀斑形成单位为2.5×10~7pfu/ml;pcDNA3.1/K5、G47δ对BIU-87、EJ细胞增殖有抑制作用,而且抑制率与G47δ剂量、作用时间正相关,联合作用抑制率比其单一作用要强;荧光显微镜观测,K5-EGFP融合蛋白在癌细胞胞浆、胞核中均有表达,G47δ对其定位并无影响;pcDNA3.1/K5对G47δ繁殖无明显影响,蚀斑形成单位数基本相同;pcDNA3.1/K5转染癌细胞后,RT-PCR扩增K5 mRNA条带位于250bp、500bp之间,符合K5核苷酸大小。
3.G47δ联合MMC抗膀胱癌效应研究:G47δ、MMC对BIU-87、EJ细胞增殖均有抑制作用,而且抑制率与G47δ、MMC的剂量和作用时间正相关,Chou-Talalay法分析合用指数CI_x＜1,Isobologram法分析q＜1,表明二者具有协同作用;G47δ对癌细胞的增殖抑制作用比野生型HSV-1明显要强;MMC对G47δ繁殖无明显影响,蚀斑形成单位数基本相同。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:PCR扩增得到552bp基因片段,并成功插入pcDNA3.1质粒,基因测序正确;SOE法所构建融合基因ES与K5中间的Linker为(Gly4Ser)3,ES-K5融合基因成功插入pcDNA3.1和pEGFP-n2真核表达质粒,基因测序正确。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:膀胱癌患者血清、尿液中VEGF、AS、ES、K5表达水平与膀胱癌分级、分期正相关;VEGF、AS、ES在癌组织中的表达也与分期正相关。
结论
1.K5基因的克隆、优化表达、纯化及活性鉴定:
1)从膀胱癌组织能克隆出Kringle5基因。
2)对蛋白表达条件参数优化后,确定诱导温度为37℃,IPTG浓度为1mmol/L,时间为6h,pGEX-5X-1/K5在BL21中表达最佳。
3)含重组质粒pGEX-5X-1/K5大肠杆菌表达产物量较多且易纯化。
2.pcDNA3.1/K5联合G47δ抗膀胱癌效应研究:
1) pcDNA3.1/K5、G47δ对膀胱癌细胞增殖均有抑制作用,而且抑制率与G47δ剂量、作用时间正相关,pcDNA3.1/K5与G47δ联合作用抑制率比其单一作用要强。
2) pcDNh3.1/K5对G47δ病毒繁殖无明显影响。
3) pcDNA3.1/K5转染癌细胞后,能在细胞内稳定表达。
3.G47δ联合MMC抗膀胱癌效应研究:
1) G47δ、MMC对膀胱癌细胞增殖均有抑制作用,抑制率与G47δ、MMC的剂量和作用时间正相关,二者合用具有协同作用。
2) G47δ对癌细胞的增殖抑制作用比野生型HSV-1明显要强。
3) MMC对G47δ繁殖无明显影响。
4.ES基因的克隆、ES-K5融合基因拼接及其真核表达质粒的构建:
1)从膀胱癌组织能克隆出Endostatin基因。
2) SOE法所构建Linker能把ES与K5拼接起来,并能成功插入到真核表达质粒中。
5.膀胱癌患者血、尿及癌组织中血管生成因子和抑制因子的检测:
1) VEGF、AS、ES、K5在膀胱癌中分泌表达与分级、分期正相关。
2)肿瘤血管新生正性和负性调控平衡被打破的原因可能是由于血管生成因子与血管生成抑制因子表达分泌均增多、增强,但以前者更为显著。
3)去除原发肿瘤后微转移灶迅速生长的原因是由于微转移灶中血管生成因子与由原发肿瘤所分泌的血管生成抑制因子来源减少而使调控平衡被打破,但这一机制不能合理解释血管生成抑制因子表达量与肿瘤分级、分期正相关的现象,有待于进一步研究。
The third-generation oncolytic herpes simplex virus G47δ(G47δ) can kill cancer cells more stronger and faster than the second-generation oncolytic HSV G207,it has already been proved by results of experimental research.The growth of primary and metastatic cancers can be restrained by endogenous angiogenesis inhibitors with merits of little immunogenicity or adverse reactions.Mitomycin C(MMC) as an intravesical chemotherapy drug is widely used to treat urothelial carcinoma of bladder after transurethral resection of bladder tumor(TURBt).It is possible to exert drug synergism to combine oncolytic herpes simplex virus G47δwith angiogenesis inhibitor or MMC on urothelial carcinoma of bladder.
Objective
1.To investigate whether the Kringle 5(K5) gene could be cloned from the human bladder carcinoma tissue,and to identify biological activity of bacterial expressed recombinant K5 protein.
2.To investigate the killing effect of G47δor pcDNA3.1/K5 on bladder cancer cells,and to evaluate the drug synergism of the combination of the two drugs.
3.To investigate the drug synergism of G47δand MMC on killing bladder cancer cells.
4.To investigate whether the Endostatin(ES) gene could be cloned from the human bladder carcinoma tissue,and the method of ES fused with K5 gene.
5.To investigate the correlation of pathologic grade and clinical stage with expression level of VEGF(vascular endothelial growth factor),Angiostatin(AS), ES,K5 in serum,urine,or cancer tissue.
Materials and Methods
1.Cloning,optimal expression,purification and activity identification of K 5: Total RNA was extracted from human bladder carcinoma tissue,then the K5 cDNA was amplified by RT-PCR.A recombinant prokaryotic expression vector pGEX-5X-1/K5 was constructed and the K5 protein was expressed in engineering bacteria.K5 was purified by tagged GST agarose 4B affinity column chromatography,the anti-proliferative effects of K5 on ECV304 were examined by MTS assay.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:DNA were extracted from G47δand wild-type HSV-1,then the target fragments amplified by PCR were identified by agarose gel electrophoresis and gene sequencing technologies; Virus titer was determined by virus plaque test;A eukaryotic expression vector pcDNA3.1/K5 was constructed and pcDNA3.1/K5 was transferred into human urinary bladder carcinoma cell line BIU-87 or EJ by polyfect liposome,subsequently,the cells were infected with G47δ,then the anti-proliferative effects of pcDNA3.1/K5 and G47δon BIU-87 or EJ cell were examined by MTS assay;Recombinant plasmid of pEGFP-n2/K5 was constructed and the plasmid was transferred into cancer cells,and the cells were infected with G47δsubsequently,the location of K5 in cells was observed through fluorescence microscope;The effects of pcDNA3.1/K5 on replication of G47δwas assessed using virus plaque test;K5 mRNA was detected by RT-PCR after pcDNA3.1/K5 was transferred into cancer cells by PolyFect liposome.
3.Combining MMC with G47δon killing bladder cancer cells:The cancer cells were infected with G47δ,1h later,MMC was added,the anti-proliferative effects of MMC and G47δon BIU-87 or EJ cells were examined by MTS assay,the combination index (CI)-isobologram of Chou-Talalay analysis was used to analyze virus and drug combinations;The anti-proliferative effects of wild-type HSV-1 and G47δon cancer cell were assessed by MTS assay;The effects of MMC on replication of G47δwas assessed using virus plaque test.
4.Cloning of ES,ES fused with K5 gene and eukaryotic expression vector with ES-K5 was constructed:Total RNA was extracted from human bladder carcinoma tissue,then the ES cDNA was amplified by RT-PCR;The fusion gene of ES-K5 was artificially synthesized by splicing by overlap extension(SOE) method and inserted into eukaryotic expression vectors such as pcDNA3.1,pEGFP-n2,then the recombinant plasmids were identified by gene sequencing technologies.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:Expression level of VEGF,AS,ES,K5 in serum and urine were detected with ELISA,and expression level of them in cancer tissue was detected with IHC,then correlation of pathologic grade and clinical stage with the expression level of VEGF,AS, ES,K5 was analyzed.
Results
1.Cloning,optimal expression,purification and activity identification of K 5: The acquired gene was 282bp,and it was inserted into pGEX-5X-1 plasmid successfully; The optimal parameters of expressing K5 in prokaryotie expression system pGEX-5X-1 are: engineering bacteria for E.coli BL21,temperature for 37℃,concentration of IPTG for 1 mmol/L,time for 6h;K5 protein,molecular weight of 12 kD,was obtained after digested by thrombin;K5 protein showed effective in specifically inhibiting proliferation of ECV304 and its optimum concentration was 5μg/ml.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:G47δvirus can incubate very rapidly in Vero cell;Agarose electrophoresis shows:the target fragment of G47δamplified by PCR was between 250bp and 500bp,but the target fragment of wild-type HSV-1 was between 500bp and 750bp,DNA sequences of two viruses were right by gene sequencing analysis,these indicated that the recombinant virus of G47δwas constructed successfully;The virus titer was 2.5×10~7 pfu/ml by virus plaque test;Both pcDNA3.1/K5 and G47δcould restrain the proliferation of BIU-87 and EJ cells, the inhibition effects were positively correlated with their action time and dosage,and combining pcDNA3.1/K5 with G47δcould cause the greater inhibition than one of them; G47δdid not disturb the location of K5 in cytoplasm and karyon;pcDNA3.1/K5 hardly disturbed on replication of G47δ,the number of plaque forming unit was same;K5 mRNA was between 250bp and 500bp,which was accorded with the molecular weight of K5.
3.Combining MMC with G47δon killing bladder cancer cells:Both MMC and G47δcould restrain the proliferation of BIU-87 and EJ cells,the inhibition effects were positively correlated with their action time and dosage,and combination index<1 which indicated the drug synergism;G47δcaused the greater inhibition than wild-type HSV-1; MMC hardly disturbed on replication of G47δ,the number of plaque forming unit was same.
4.Cloning of ES,ES fused with K5 gene and eukaryotie expression vector with ES-K5 was constructed:The acquired gene was 552bp,and it was inserted into pcDNA3.1 plasmid successfully;The fusion gene of ES-K5 was constructed successfully by the method of SOE,the linker was(Gly4Ser)3,and ES-K5 was inserted into pcDNA3.1 and pEGFP-n2 plasmids successfully.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:Expression level of VEGF,AS,ES,K5 in serum and urine were positively correlated with pathologic grade and clinical stage;expression level of them in cancer tissue was positively correlated with pathologic grade too.
Conclusions
1.Cloning,optimal expression,purification and activity identification of K5:
1) K5 gene was cloned successfully from human bladder carcinoma tissue.
2) The optimal parameters of expressing K5 in prokaryotic expression system pGEX-5X-1 are:engineering bacteria for E.coli BL21,temperature for 37℃, concentration of IPTG for 1 mmol/L,time for 6h.
3) K5 protein has a large expression level and easy to purify by way of E.coli containing recombinant plasmid pGEX-5X-1/K5.
2.Combining pcDNA3.1/K5 with G47δon killing bladder cancer cells:
1) pcDNA3.1/K5 and G47δcould restrain the proliferation of bladder cancer cell,the inhibition effects were positively correlated with their action time and dosage,and combining pcDNA3.1/K5 with G47δcaused the greater inhibition than one of them.
2) pcDNA3.1/K5 hardly disturbed on replication of G47δ.
3) pcDNA3.1/K5 can stably express in cells
3.Combining MMC with G47δon killing bladder cancer cells:
1) MMC and G47δcould restrain the proliferation of bladder cancer cells,the inhibition effects were positively correlated with their action time and dosage,and combination can produce synergistc effect.
2) G47δcaused greater inhibition than HSV-1.
3) MMC hardly disturbed on replication of G47δ.
4.Cloning of ES,ES fused with K5 gene and eukaryotic expression vector with ES-K5 was constructed:
1) ES gene was cloned successfully from human bladder carcinoma tissue.
2) Fusion gene of ES-K5 could be inserted into eukaryotic expression vectors.
5.Detection of the expression level of VEGF,AS,ES,K5 in serum,urine,or cancer tissue:
1) Expression level of VEGF,AS,ES,K5 in bladder cancer was positively correlated with pathologic grade and clinical stage.
2) Positive and negative regulation control angiogenesis,and the balance is broken in tumor angiogenesis,the possible reason was that it increased the expression and secretion of both angiogenesis factors and angiogenesis inhibitors,but biological activity of angiogenesis factors is stronger.
3) The reason of a rapid progression of metastasis after surgical resection of the primary tumor is that the reduction of production and secretion of antimitotic factors by the cells of the primary tumor that inhibit the proliferation of metastatic cells,but it can not reasonably explain that expression level of angiogenesis inhibitor were positively correlated with pathologic grade and clinical stage.
引文
1.Perri SR,Martineau D,Francois M,et al.Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways.Mol Cancer Ther,2007,6(2):441-449.
2.Cao Y,Cao R,Veitonm(a|¨)ki N.Kringle structures and antiangiogenesis.Curr Med Chem Anticancer Agents,2002,2(6):667-681.
3.Hanford HA,Wong CA,Kassan H,et al.Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.Cancer Res,2003,63(14):4275-4280.
4.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
5.Nguyen TM,Subramanian IV,Kelekar A,et al.Kringle 5 of human plasminogen,an angiogenesis inhibitor,induces both autophagy and apoptotic death in endothelial cells.Blood,2007,109(11):4793-4802.
6.Zhang Z,Ma JX,Gao G;et al.Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.Invest Ophthalmol Vis Sci,2005,46(11):4062-4071.
7.Cao Y,Chen A,An SS,et al.Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem, 1997,272(36): 22924 -22928.
8. Gonzalez-Gronow M, Kalfa T, Johnson CE, et al. The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. J Biol Chem, 2003,278(29):27312-27318.
9. Yang X, Cheng R, Li C, et al. Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol Ther, 2006, 5(4):399-405.
10. Jin GH, Ma DY, Wu N, et al. Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. Int J Cancer,2007, 121(11):2539-2546.
11. Helboe L, M(?)ller M. Localization of somatostatin receptors at the light and electron microscopial level by using antibodies raised against fusion proteins. Prog Histochem Cytochem, 2000, 35(1):3-64.
1. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr, 2008,2(3):208-213.
2. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med, 1995, 1(9):938-943.
3. He B, Chou J, Brandimarti R, et al. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol, 1997,71(8):6049-6054.
4. Todo T, Ebright MI, Fong Y, et al. Oncolytic herpes simplex virus (G207)therapy for cancer: from basic to clinical. In: Maruta H, editor. Tumor Suppressing Viruses, Genes, and Drugs-Innovative Cancer Therapy Approaches. San Diego: Academic Press. 2001,45-75.
5. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther, 1999,10(17):2741-2755.
6. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J, 2001,15(7):1306-1328.
7. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther, 2000, 11(12):1683-1693.
8. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 2000, 7(10):867-874.
9. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996,15(17):4759-4766.
10. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class Ⅰ presentation and tumor cell killing.Proc Natl Acad Sci U S A,2001,98(11):6396-6401.
11.Wakimoto H,Kesari S,Farrell CJ,et al.Human glioblastoma-derived cancer stem cells:establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res,2009,69(8):3472-3481.
12.Kolodkin Gal D,Edden Y,Hartshtark Z,et al.Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.Gene Ther,2009,16(7):905-915.
13.Passer BJ,Wu CL,Wu S,et al.Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.Gene Ther,2009,16(12):1477-1482.
14.Liu R,Martuza RL,Rabkin SD,et al.Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.Gene Ther,2005,12(8):647-654.
15.Messerli SM,Prabhakar S,Tang Y,et al.Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.Hum Gene Ther,2006,17(1):20-30.
16.Prabhakar S,Messerli SM,Stemmer-Rachamimov AO,et al.Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.Cancer Gene Ther,2007,14(5):460-467.
17.Perri SR,Martineau D,Francois M,et al.Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways.Mol Cancer Ther,2007,6(2):441-449.
18.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
19.石长清,李正东,张群华,等.转染人血纤溶酶原Kringle 5基因对人胰腺癌PC3细胞的影响.中华医学杂志,2004,84(21):1827-1831.
20.蔡卫斌,程锐,徐祖敏,等.人纤溶酶原K5体内抑制Lewis肺癌肿瘤生长与 转移.中山大学学报(医学科学版),2008,29(5):566-569.
21.刘倩平,杨霞,李朝阳,等.人纤维蛋白溶酶原kringle5(K5)抑制小鼠肝癌的血管生成和肿瘤生长.中山大学学报(医学科学版),2005,26(4):380-383.
22.Aghi M,Rabkin SD,Martuza RL.Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.Cancer Res,2007,67(2):440-444.
23.Yang CT,Lin YC,Lin CL,et al.Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.Anticancer Res,2005,25(3B):2049-2054.
24.Liu TC,Zhang T,Fukuhara H,et al.Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.Clin Cancer Res,2006,12(22):6791-6799.
25.Liu TC,Zhang T,Fukuhara H,et al.Oncolytic HSV armed with platelet factor 4,an antiangiogenic agent,shows enhanced efficacy.Mol Ther,2006,14(6):789-797.
26.Passer BJ,Castelo-Branco P,Buhrman JS,et al.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.Cancer Gene Ther,2009,16(7):551-560.
1.Chou TC,Talalay P.Quantitative analysis of dose-effect relationships:the combined effects of multiple drugs or enzyme inhibitors.Adv Enzyme Regul,1984,22:27-55.
2.Chou TC,Motzer RJ,Tong Y,et al.terized quantitation of synergism and antagonism of taxol,topotecan,and cisplatin against human teratocarcinoma cell growth:a rational approach to clinical protocol design.J Natl Cancer Inst.1994,86(20):1517-1524.
3.Chou TC,Dong H,Zhang X,et al.Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent,fludelone,via parenteral or oral route.Cancer Res,2005,65(20):9445-9454.
4.Chou TC.Theoretical basis,experimental design,and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006,8(3):621-81.
5. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 2010, 70(2):440-446.
6. Mackay ML, Milne K, Gould IM. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents, 2000,15(2):125-129.
7. Gennings C, Carter WH Jr, Campbell ED, et al. Isobolographic characterization of drug interactions incorporating biological variability. J Pharmacol Exp Ther, 1990,252(1):208-217.
8. Bradner WT. Mitomycin C: a clinical update. Cancer Treat Rev, 2001,27(1):35-50.
9. Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf, 2007,6(1):27-32.
10. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther, 1999, 10(18):3013-3029.
11. Mullerad M, Bochner BH, Adusumilli PS, et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol, 2005,174(2):741-746.
12. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J, 2004,18(9): 1001-1003.
13. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology, 2000,267(2):335-349.
14. Hollander MC, Zhan Q, Bae I, et al. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem, 1997, 272(21):13731-13737.
15. Passer BJ, Castelo-Branco P, Buhrman JS, et al. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther, 2009, 16(7):551-560.
16. Hoffmann D, Bangen JM, Bayer W, Wildner O. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther, 2006, 13(21):1534-1544.
1.毛晓燕,李仁德,梁国栋,等.血管抑制素和內皮抑制素的协同作用.医学分子生物学杂志,2005,2(1):49-52.
2.Weiss JM,Shivakumar R,Feller S,et al.Rapid,in vivo,evaluation of antiangiogenic and antineoplastic gene products by nonviral transfectionof tumor cells.Cancer Gene Ther,2004,11(5):346-353.
3.Scappaticci FA,Contreras A,Smith R,et al.Statin-AE:a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.Angiogenesis,2001,4(4):263-258.
4.Ponnazhagan S,Mahendra G,Lima J,et al.Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.Hum Gerie Ther,2004,15(9):856-864.
5. Li X, Liu YH, Lee SJ, et al. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res, 2008, 14(1): 291-299.
6. Tysome JR, Briat A, Alusi G,et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther, 2009, 16(10):1223-1233.
7. Yang CT, Lin YC, Lin CL, et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res, 2005, 25(3B): 2049-2054.
8. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res, 2005,65 (11): 4663-4672.
9. BertoE, Bozac A, Volpi I, et al. Antitumor effects of non-replicativeherpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.Cancer Gene Ther, 2007, 14(9): 791-801.
10. Schmidt A, Sommer F, Reiner M, et al. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int, 2005,95(1): 174-179.
1.Jin J,Guan M,Sima 7,et al.Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.Cornea,2003,22(5):473-477.
2.Tombran-Tink J.PEDF in angiogenic eye diseases.Curr Mol Med,2010,10(3):267-278.
3.Nam DH,Oh J,Roh JH,Huh K.Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.Ophthalmologica.2009,223(3):188-191.
4.郑凯,张绍增,王养民,等.膀胱移行细胞癌患者血管抑素的定量检测及其临床意义.西北国防医学杂志,2003,24(6):404-406.
5.管考鹏,侯树坤,王晓峰,等.膀胱癌组织及血清中内皮抑素表达的意义.中华泌尿外科杂志,2003,24(8):539-541.
6. Guan KP, Ye HY, Yan Z, et al. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology, 2003, 61(4): 719-723.
7. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer, 2000, 86 (6): 760-767.
8. Beecken WD, Engl T, Jonas D, et al. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med, 2009,23 (2): 261-266.
1.Krisky DM,Marconi PC,Oligino TJ,et al.Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications.Gene Ther,1998,5(11):1517-1530.
2.Marconi P,Manservigi R,Epstein AL.HSV-1 derived helper-independent defective vectors,replicating vectors and amplicon vectors,for the treatment of brain diseases.Curr Opin Drug Discov Devel,2010,13(2):169-183.
3.Valyi-Nagy T,Gesser RM,Raengsakulrach B,et al.A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement.Virology,1994,199(2):484-490.
4.He B,Chou J,Brandimarti R,et al.Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1:failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene.J Virol,1997,71(8):6049-6054.
5. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res, 1994, 54(15):3963-3966.
6. Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther, 2000, 7(7): 1051-1059.
7. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci, 2008,13:2060-2064.
8. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment ofmalignant gliomas. Nat Med, 1995, l(9):938-943.
9. Todo T, Ebright MI, Fong Y, et al. Oncolytic herpes simplex virus (G207) therapy for cancer: from basic to clinical. In: Maruta H, editor. Tumor Suppressing Viruses, Genes, and Drugs-Innovative Cancer Therapy Approaches. San Diego: Academic Press. 2001,45-75.
10. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther,1999,10(17):2741-2755.
11. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J, 2001, 15(7):1306-1328.
12. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther, 2000, 11(12):1683-1693.
13. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther, 2001, 12(8):999-1010.
14. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 2000, 7(10):867-874.
15. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996, 15(17):4759-4766.
16. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA,2001, 98(11):6396-6401.
17. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res, 2009, 69(8):3472-3481.
18. Kolodkin Gal D, Edden Y, Hartshtark Z, et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther, 2009,16(7):905-915.
19. Passer BJ, Wu CL, Wu S, et al. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther, 2009,16(12):1477-1482.
20. Liu R, Martuza RL, Rabkin SD, et al. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther, 2005, 12(8):647-654.
21. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res, 2005, 65(23):10663-10668.
22. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res, 2007,67(2):440-444.
23. Berto E, Bozac A, Volpi I, et al. Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. Cancer Gene Ther, 2007, 14(9):791-801.
24. Yang CT, Lin YC, Lin CL, et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res, 2005,25(3B):2049-2054.
25. Liu TC, Zhang T, Fukuhara H,et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural rumors. Clin Cancer Res, 2006,12(22):6791-6799.
26. Liu TC, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther, 2006, 14(6): 789-797.
1.Xue F,Gu Z,Feng JA.LINKER:a web server to generate peptide sequences with extended conformation.Nucleic Acids Res,2004,32(Web Server issue):W562-565.
2.Gustavsson M,Lehti(o|¨) J,Denman S,et al.Stable linker peptides for a cellulose-binding domain-lipase fusion protein expressed in Pichia pastoris.Protein Eng,2001,14(9):711-715.
3.Robinson CR,Sauer RT.Optimizing the stability of single-chain proteins by linker length and composition mutagenesis.Proc Natl Acad Sci U S A,1998,95(11):5929-5934.
4.Ribatti D.Endogenous inhibitors of angiogenesis:a historical review.Leuk Res,2009,33(5):638-644.
5.毛晓燕,李仁德,梁国栋,等.血管抑制素和内皮抑制素的协同作用.医学分子生物学杂志,2005,2(1):49-52.
6.潘静坤,赵卉,田磊,等.体外培养下可持续分泌人血管抑素和内皮抑素基因工程细胞对血管生成的抑制效应.中同组织工程研究与Ⅰ临床,2009,13(20):3886-3889.
7.Weiss JM,Shivakumar R,Feller S,et al.Rapid,in vivo,evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells.Cancer Gene Ther,2004,11(5):346-353.
8.Scappaticci FA,Contreras A,Smith R,et al.Statin-AE:a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.Angiogenesis,2001,4(4):263-268.
9.毛晓燕,刘卫滨,付士红,等.血管抑制素和内皮抑制素在大肠杆菌中的融合表达与鉴定.生物医学工程学杂志,2006,23(5):1086-1091.
10.Ponnazhagan S,Mahendra G,Lima J,et al.Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.Hum Gene Ther,2004,15(9):856-864.
11.Li X,Raikwar SP,Liu YH,et al.Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene.Mol Cancer Ther.2006,5(3):676-684.
12.Li X,Liu YH,Lee SJ,et al.Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.Clin Cancer Res,2008,14(1):291-299.
13.Tysome JR,Briat A,Alusi G,et al.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.Gene Ther,2009,16(10):1223-1233.
14.Yang CT,Lin YC,Lin CL,et al.Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.Anticancer Res,2005,25(3B):2049-2054.
15.Cao Y,Cao R,Veitonm(a|¨)ki N.Kringle structures and antiangiogenesis.Curt Med Chem Anticancer Agents,2002,2(6):667-681.
16.Geiger JH,Cnudde SE.What the structure of angiostatin may tell us about its mechanism of action.J Thromb Haemost,2004,2(1):23-34.
17.Hanford HA,Wong CA,Kassan H,et al.Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.Cancer Res,2003,63(14):4275-4280.
18.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
19.李慧瑾,张伟峰,王东阳,等.人endostatin、K5及endostatin-K5重组腺病毒载体的构建及其表达.细胞与分子免疫学杂志,2009,25(7):577-580.
20.Murthy RC,McFarland TJ,Yoken J,Chen S,Barone C,Burke D,Zhang Y,Appukuttan B,Stout JT.Corneal transduction to inhibit angiogenesis and graft failure.Invest Ophthalmol Vis Sci,2003,44(5):1837-1842.
21.Berto E,Bozac A,Volpi I,et al.Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.Cancer Gene Ther,2007,14(9):791-801.
22.沈先荣,吉冬梅,贾福星,等.一种新的血管生成抑制因子--TSF的设计及表达.中华航海医学与高气压医学杂志,2002,9(4):239-245.
23.李喆,潘欣,潘卫,等.内皮抑素-可溶性血管内皮细胞生长抑制因子融合基因重组腺病毒的包装与鉴定.世界华人消化杂志,2003,11(7):741-744.
24.王泳,柳林,潘欣.重组人内皮抑素与血管内皮生长抑制因子融合基因对角膜新生血管内皮细胞的协同作用.中国临床康,2006,10(33):85-88.
25.Lu H,Yuan H,Li Y.Expression of human plasminogen kringle 5 as fusion protein with truncated hIFNgamma gene in Escherichia coli.J Biotechnol,2002,94(3):277-285.
26.Kim KS,Kim HS,Park JS,et al.Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes.Cancer Gene Ther,2004,11(6):441-449.
1.Hautmann RE,Gschwend JE,de Petriconi RC,et al.Cystectomy for transitional cell carcinoma of the bladder:results of a surgery only series in the neobladder era.J Urol,2006,176(2):486-492.
2.Spitz A,Stein JP,Lieskovsky G,et al.Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy:a new technique.J Urol,1999,161(6):1761-1764.
3.Colombo R,Bertini R,Salonia A,et al.Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer:an innovative surgical approach.J Urol,2001,165(1):51-55.
4.Terrone C,Cracco C,Scarpa RM,et al.Supra-ampullar cystectomy with preservation of sexual function and ileal orthotopic reservoir for bladder tumor:twenty years of experience.Eur Urol,2004,46(2):264-269.
5.Nieuwenhuijzen JA,Meinhardt W,Horenblas S.Clinical outcomes after sexuality preserving cystectomy and neobladder(prostate sparing cystectomy)in 44 patients.J Urol,2005,173(4):1314-1317.
6.Hautmann RE,Stein JP.Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer:a step in the wrong direction.Urol Clin North Am,2005,32(2):177-185.
7.Tal R,Baniel J.Sexual function-preserving cystectomy.Urology,2005,66(2):235-241.
8.Yossepowitch O,Dalbagni G.Transitional cell carcinoma of the bladder in young adults:presentation,natural history and outcome.J Urol,2002,168(1):61-66.
9.Vallancien G,Abou EF,Cathelineau X,et al:Cystectomy with prostate sparing for bladder cancer in 100 patients:10-year experience.J Urol,2002,168(6):2413-2417.
10.Colombo R,Bertin R,Salonia A,et al:Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer.J Urol,2004,171(5):1819-1822.
11.Muto G,Bardari F,D'Urso L,et al:Seminal sparing cystectomy and ileocapsuloplasty:long-term followup results.J Urol,2004,172(1):76-80.
12.Horenblas S,Meinhardt W,Ijzerman W,et al:Sexuality preserving cystectomy and neobladder:initial results.J Urol,2001,166(3):837-840.
13.Revelo MP,Cookson MS,Chang SS,et al.Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies:implications for possible apical sparing surgery.J Urol,2004,171(2Pt1):646-651.
14.Prange W,Erbersdobler A,Hammerer P,et al.High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens.Eur Urol.2001,39(Suppl4):30-31.
15.Freeman JA,Tarter TA,Esrig D,et al.Urethral recurrence in patients with orthotopic ileal neobladders.J Urol,1996,156(5):1615-1619.
16.徐鸿毅,邱学德,石永福,等.原位肠代膀胱术远期疗效评价(附266例报告).中华泌尿外科杂志,2005,26(8):551-554.
17.石永福,柯昌兴,徐鸿毅,等.保留生育功能的原位尿流改道术六例报告.中华泌尿外科杂志,2007,28(6):368-371.
18.Martis G,D'Elia G,Diana M,et al.Prostatic capsule- and nerve-sparing cystectomy in organ-confined bladder cancer:preliminary results.World J Surg,2005,29(10):1277-1281.
19.Kubin M,Wagner G,and Fugl-Meyer AR:Epidemiology of erectile dysfunction.Int J Impot Res,2003,15(1):63-71.
2.Cao Y,Cao R,Veitonm(a|¨)ki N.Kringle structures and antiangiogenesis.Curr Med Chem Anticancer Agents,2002,2(6):667-681.
3.Hanford HA,Wong CA,Kassan H,et al.Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.Cancer Res,2003,63(14):4275-4280.
4.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
5.Nguyen TM,Subramanian IV,Kelekar A,et al.Kringle 5 of human plasminogen,an angiogenesis inhibitor,induces both autophagy and apoptotic death in endothelial cells.Blood,2007,109(11):4793-4802.
6.Zhang Z,Ma JX,Gao G;et al.Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.Invest Ophthalmol Vis Sci,2005,46(11):4062-4071.
7.Cao Y,Chen A,An SS,et al.Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem, 1997,272(36): 22924 -22928.
8. Gonzalez-Gronow M, Kalfa T, Johnson CE, et al. The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. J Biol Chem, 2003,278(29):27312-27318.
9. Yang X, Cheng R, Li C, et al. Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol Ther, 2006, 5(4):399-405.
10. Jin GH, Ma DY, Wu N, et al. Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. Int J Cancer,2007, 121(11):2539-2546.
11. Helboe L, M(?)ller M. Localization of somatostatin receptors at the light and electron microscopial level by using antibodies raised against fusion proteins. Prog Histochem Cytochem, 2000, 35(1):3-64.
1. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr, 2008,2(3):208-213.
2. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med, 1995, 1(9):938-943.
3. He B, Chou J, Brandimarti R, et al. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol, 1997,71(8):6049-6054.
4. Todo T, Ebright MI, Fong Y, et al. Oncolytic herpes simplex virus (G207)therapy for cancer: from basic to clinical. In: Maruta H, editor. Tumor Suppressing Viruses, Genes, and Drugs-Innovative Cancer Therapy Approaches. San Diego: Academic Press. 2001,45-75.
5. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther, 1999,10(17):2741-2755.
6. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J, 2001,15(7):1306-1328.
7. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther, 2000, 11(12):1683-1693.
8. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 2000, 7(10):867-874.
9. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996,15(17):4759-4766.
10. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class Ⅰ presentation and tumor cell killing.Proc Natl Acad Sci U S A,2001,98(11):6396-6401.
11.Wakimoto H,Kesari S,Farrell CJ,et al.Human glioblastoma-derived cancer stem cells:establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res,2009,69(8):3472-3481.
12.Kolodkin Gal D,Edden Y,Hartshtark Z,et al.Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.Gene Ther,2009,16(7):905-915.
13.Passer BJ,Wu CL,Wu S,et al.Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.Gene Ther,2009,16(12):1477-1482.
14.Liu R,Martuza RL,Rabkin SD,et al.Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.Gene Ther,2005,12(8):647-654.
15.Messerli SM,Prabhakar S,Tang Y,et al.Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.Hum Gene Ther,2006,17(1):20-30.
16.Prabhakar S,Messerli SM,Stemmer-Rachamimov AO,et al.Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.Cancer Gene Ther,2007,14(5):460-467.
17.Perri SR,Martineau D,Francois M,et al.Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways.Mol Cancer Ther,2007,6(2):441-449.
18.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
19.石长清,李正东,张群华,等.转染人血纤溶酶原Kringle 5基因对人胰腺癌PC3细胞的影响.中华医学杂志,2004,84(21):1827-1831.
20.蔡卫斌,程锐,徐祖敏,等.人纤溶酶原K5体内抑制Lewis肺癌肿瘤生长与 转移.中山大学学报(医学科学版),2008,29(5):566-569.
21.刘倩平,杨霞,李朝阳,等.人纤维蛋白溶酶原kringle5(K5)抑制小鼠肝癌的血管生成和肿瘤生长.中山大学学报(医学科学版),2005,26(4):380-383.
22.Aghi M,Rabkin SD,Martuza RL.Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.Cancer Res,2007,67(2):440-444.
23.Yang CT,Lin YC,Lin CL,et al.Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.Anticancer Res,2005,25(3B):2049-2054.
24.Liu TC,Zhang T,Fukuhara H,et al.Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.Clin Cancer Res,2006,12(22):6791-6799.
25.Liu TC,Zhang T,Fukuhara H,et al.Oncolytic HSV armed with platelet factor 4,an antiangiogenic agent,shows enhanced efficacy.Mol Ther,2006,14(6):789-797.
26.Passer BJ,Castelo-Branco P,Buhrman JS,et al.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.Cancer Gene Ther,2009,16(7):551-560.
1.Chou TC,Talalay P.Quantitative analysis of dose-effect relationships:the combined effects of multiple drugs or enzyme inhibitors.Adv Enzyme Regul,1984,22:27-55.
2.Chou TC,Motzer RJ,Tong Y,et al.terized quantitation of synergism and antagonism of taxol,topotecan,and cisplatin against human teratocarcinoma cell growth:a rational approach to clinical protocol design.J Natl Cancer Inst.1994,86(20):1517-1524.
3.Chou TC,Dong H,Zhang X,et al.Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent,fludelone,via parenteral or oral route.Cancer Res,2005,65(20):9445-9454.
4.Chou TC.Theoretical basis,experimental design,and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006,8(3):621-81.
5. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 2010, 70(2):440-446.
6. Mackay ML, Milne K, Gould IM. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents, 2000,15(2):125-129.
7. Gennings C, Carter WH Jr, Campbell ED, et al. Isobolographic characterization of drug interactions incorporating biological variability. J Pharmacol Exp Ther, 1990,252(1):208-217.
8. Bradner WT. Mitomycin C: a clinical update. Cancer Treat Rev, 2001,27(1):35-50.
9. Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf, 2007,6(1):27-32.
10. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther, 1999, 10(18):3013-3029.
11. Mullerad M, Bochner BH, Adusumilli PS, et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol, 2005,174(2):741-746.
12. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J, 2004,18(9): 1001-1003.
13. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology, 2000,267(2):335-349.
14. Hollander MC, Zhan Q, Bae I, et al. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem, 1997, 272(21):13731-13737.
15. Passer BJ, Castelo-Branco P, Buhrman JS, et al. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther, 2009, 16(7):551-560.
16. Hoffmann D, Bangen JM, Bayer W, Wildner O. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther, 2006, 13(21):1534-1544.
1.毛晓燕,李仁德,梁国栋,等.血管抑制素和內皮抑制素的协同作用.医学分子生物学杂志,2005,2(1):49-52.
2.Weiss JM,Shivakumar R,Feller S,et al.Rapid,in vivo,evaluation of antiangiogenic and antineoplastic gene products by nonviral transfectionof tumor cells.Cancer Gene Ther,2004,11(5):346-353.
3.Scappaticci FA,Contreras A,Smith R,et al.Statin-AE:a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.Angiogenesis,2001,4(4):263-258.
4.Ponnazhagan S,Mahendra G,Lima J,et al.Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.Hum Gerie Ther,2004,15(9):856-864.
5. Li X, Liu YH, Lee SJ, et al. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res, 2008, 14(1): 291-299.
6. Tysome JR, Briat A, Alusi G,et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther, 2009, 16(10):1223-1233.
7. Yang CT, Lin YC, Lin CL, et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res, 2005, 25(3B): 2049-2054.
8. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res, 2005,65 (11): 4663-4672.
9. BertoE, Bozac A, Volpi I, et al. Antitumor effects of non-replicativeherpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.Cancer Gene Ther, 2007, 14(9): 791-801.
10. Schmidt A, Sommer F, Reiner M, et al. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int, 2005,95(1): 174-179.
1.Jin J,Guan M,Sima 7,et al.Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.Cornea,2003,22(5):473-477.
2.Tombran-Tink J.PEDF in angiogenic eye diseases.Curr Mol Med,2010,10(3):267-278.
3.Nam DH,Oh J,Roh JH,Huh K.Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.Ophthalmologica.2009,223(3):188-191.
4.郑凯,张绍增,王养民,等.膀胱移行细胞癌患者血管抑素的定量检测及其临床意义.西北国防医学杂志,2003,24(6):404-406.
5.管考鹏,侯树坤,王晓峰,等.膀胱癌组织及血清中内皮抑素表达的意义.中华泌尿外科杂志,2003,24(8):539-541.
6. Guan KP, Ye HY, Yan Z, et al. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology, 2003, 61(4): 719-723.
7. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer, 2000, 86 (6): 760-767.
8. Beecken WD, Engl T, Jonas D, et al. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med, 2009,23 (2): 261-266.
1.Krisky DM,Marconi PC,Oligino TJ,et al.Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications.Gene Ther,1998,5(11):1517-1530.
2.Marconi P,Manservigi R,Epstein AL.HSV-1 derived helper-independent defective vectors,replicating vectors and amplicon vectors,for the treatment of brain diseases.Curr Opin Drug Discov Devel,2010,13(2):169-183.
3.Valyi-Nagy T,Gesser RM,Raengsakulrach B,et al.A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement.Virology,1994,199(2):484-490.
4.He B,Chou J,Brandimarti R,et al.Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1:failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene.J Virol,1997,71(8):6049-6054.
5. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res, 1994, 54(15):3963-3966.
6. Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther, 2000, 7(7): 1051-1059.
7. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci, 2008,13:2060-2064.
8. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment ofmalignant gliomas. Nat Med, 1995, l(9):938-943.
9. Todo T, Ebright MI, Fong Y, et al. Oncolytic herpes simplex virus (G207) therapy for cancer: from basic to clinical. In: Maruta H, editor. Tumor Suppressing Viruses, Genes, and Drugs-Innovative Cancer Therapy Approaches. San Diego: Academic Press. 2001,45-75.
10. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther,1999,10(17):2741-2755.
11. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J, 2001, 15(7):1306-1328.
12. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther, 2000, 11(12):1683-1693.
13. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther, 2001, 12(8):999-1010.
14. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther, 2000, 7(10):867-874.
15. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996, 15(17):4759-4766.
16. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA,2001, 98(11):6396-6401.
17. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res, 2009, 69(8):3472-3481.
18. Kolodkin Gal D, Edden Y, Hartshtark Z, et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther, 2009,16(7):905-915.
19. Passer BJ, Wu CL, Wu S, et al. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther, 2009,16(12):1477-1482.
20. Liu R, Martuza RL, Rabkin SD, et al. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther, 2005, 12(8):647-654.
21. Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res, 2005, 65(23):10663-10668.
22. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res, 2007,67(2):440-444.
23. Berto E, Bozac A, Volpi I, et al. Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. Cancer Gene Ther, 2007, 14(9):791-801.
24. Yang CT, Lin YC, Lin CL, et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res, 2005,25(3B):2049-2054.
25. Liu TC, Zhang T, Fukuhara H,et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural rumors. Clin Cancer Res, 2006,12(22):6791-6799.
26. Liu TC, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther, 2006, 14(6): 789-797.
1.Xue F,Gu Z,Feng JA.LINKER:a web server to generate peptide sequences with extended conformation.Nucleic Acids Res,2004,32(Web Server issue):W562-565.
2.Gustavsson M,Lehti(o|¨) J,Denman S,et al.Stable linker peptides for a cellulose-binding domain-lipase fusion protein expressed in Pichia pastoris.Protein Eng,2001,14(9):711-715.
3.Robinson CR,Sauer RT.Optimizing the stability of single-chain proteins by linker length and composition mutagenesis.Proc Natl Acad Sci U S A,1998,95(11):5929-5934.
4.Ribatti D.Endogenous inhibitors of angiogenesis:a historical review.Leuk Res,2009,33(5):638-644.
5.毛晓燕,李仁德,梁国栋,等.血管抑制素和内皮抑制素的协同作用.医学分子生物学杂志,2005,2(1):49-52.
6.潘静坤,赵卉,田磊,等.体外培养下可持续分泌人血管抑素和内皮抑素基因工程细胞对血管生成的抑制效应.中同组织工程研究与Ⅰ临床,2009,13(20):3886-3889.
7.Weiss JM,Shivakumar R,Feller S,et al.Rapid,in vivo,evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells.Cancer Gene Ther,2004,11(5):346-353.
8.Scappaticci FA,Contreras A,Smith R,et al.Statin-AE:a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.Angiogenesis,2001,4(4):263-268.
9.毛晓燕,刘卫滨,付士红,等.血管抑制素和内皮抑制素在大肠杆菌中的融合表达与鉴定.生物医学工程学杂志,2006,23(5):1086-1091.
10.Ponnazhagan S,Mahendra G,Lima J,et al.Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.Hum Gene Ther,2004,15(9):856-864.
11.Li X,Raikwar SP,Liu YH,et al.Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene.Mol Cancer Ther.2006,5(3):676-684.
12.Li X,Liu YH,Lee SJ,et al.Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.Clin Cancer Res,2008,14(1):291-299.
13.Tysome JR,Briat A,Alusi G,et al.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.Gene Ther,2009,16(10):1223-1233.
14.Yang CT,Lin YC,Lin CL,et al.Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.Anticancer Res,2005,25(3B):2049-2054.
15.Cao Y,Cao R,Veitonm(a|¨)ki N.Kringle structures and antiangiogenesis.Curt Med Chem Anticancer Agents,2002,2(6):667-681.
16.Geiger JH,Cnudde SE.What the structure of angiostatin may tell us about its mechanism of action.J Thromb Haemost,2004,2(1):23-34.
17.Hanford HA,Wong CA,Kassan H,et al.Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.Cancer Res,2003,63(14):4275-4280.
18.Davidson DJ,Haskell C,Majest S,et al.Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.Cancer Res,2005,65(11):4663-4672.
19.李慧瑾,张伟峰,王东阳,等.人endostatin、K5及endostatin-K5重组腺病毒载体的构建及其表达.细胞与分子免疫学杂志,2009,25(7):577-580.
20.Murthy RC,McFarland TJ,Yoken J,Chen S,Barone C,Burke D,Zhang Y,Appukuttan B,Stout JT.Corneal transduction to inhibit angiogenesis and graft failure.Invest Ophthalmol Vis Sci,2003,44(5):1837-1842.
21.Berto E,Bozac A,Volpi I,et al.Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.Cancer Gene Ther,2007,14(9):791-801.
22.沈先荣,吉冬梅,贾福星,等.一种新的血管生成抑制因子--TSF的设计及表达.中华航海医学与高气压医学杂志,2002,9(4):239-245.
23.李喆,潘欣,潘卫,等.内皮抑素-可溶性血管内皮细胞生长抑制因子融合基因重组腺病毒的包装与鉴定.世界华人消化杂志,2003,11(7):741-744.
24.王泳,柳林,潘欣.重组人内皮抑素与血管内皮生长抑制因子融合基因对角膜新生血管内皮细胞的协同作用.中国临床康,2006,10(33):85-88.
25.Lu H,Yuan H,Li Y.Expression of human plasminogen kringle 5 as fusion protein with truncated hIFNgamma gene in Escherichia coli.J Biotechnol,2002,94(3):277-285.
26.Kim KS,Kim HS,Park JS,et al.Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes.Cancer Gene Ther,2004,11(6):441-449.
1.Hautmann RE,Gschwend JE,de Petriconi RC,et al.Cystectomy for transitional cell carcinoma of the bladder:results of a surgery only series in the neobladder era.J Urol,2006,176(2):486-492.
2.Spitz A,Stein JP,Lieskovsky G,et al.Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy:a new technique.J Urol,1999,161(6):1761-1764.
3.Colombo R,Bertini R,Salonia A,et al.Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer:an innovative surgical approach.J Urol,2001,165(1):51-55.
4.Terrone C,Cracco C,Scarpa RM,et al.Supra-ampullar cystectomy with preservation of sexual function and ileal orthotopic reservoir for bladder tumor:twenty years of experience.Eur Urol,2004,46(2):264-269.
5.Nieuwenhuijzen JA,Meinhardt W,Horenblas S.Clinical outcomes after sexuality preserving cystectomy and neobladder(prostate sparing cystectomy)in 44 patients.J Urol,2005,173(4):1314-1317.
6.Hautmann RE,Stein JP.Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer:a step in the wrong direction.Urol Clin North Am,2005,32(2):177-185.
7.Tal R,Baniel J.Sexual function-preserving cystectomy.Urology,2005,66(2):235-241.
8.Yossepowitch O,Dalbagni G.Transitional cell carcinoma of the bladder in young adults:presentation,natural history and outcome.J Urol,2002,168(1):61-66.
9.Vallancien G,Abou EF,Cathelineau X,et al:Cystectomy with prostate sparing for bladder cancer in 100 patients:10-year experience.J Urol,2002,168(6):2413-2417.
10.Colombo R,Bertin R,Salonia A,et al:Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer.J Urol,2004,171(5):1819-1822.
11.Muto G,Bardari F,D'Urso L,et al:Seminal sparing cystectomy and ileocapsuloplasty:long-term followup results.J Urol,2004,172(1):76-80.
12.Horenblas S,Meinhardt W,Ijzerman W,et al:Sexuality preserving cystectomy and neobladder:initial results.J Urol,2001,166(3):837-840.
13.Revelo MP,Cookson MS,Chang SS,et al.Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies:implications for possible apical sparing surgery.J Urol,2004,171(2Pt1):646-651.
14.Prange W,Erbersdobler A,Hammerer P,et al.High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens.Eur Urol.2001,39(Suppl4):30-31.
15.Freeman JA,Tarter TA,Esrig D,et al.Urethral recurrence in patients with orthotopic ileal neobladders.J Urol,1996,156(5):1615-1619.
16.徐鸿毅,邱学德,石永福,等.原位肠代膀胱术远期疗效评价(附266例报告).中华泌尿外科杂志,2005,26(8):551-554.
17.石永福,柯昌兴,徐鸿毅,等.保留生育功能的原位尿流改道术六例报告.中华泌尿外科杂志,2007,28(6):368-371.
18.Martis G,D'Elia G,Diana M,et al.Prostatic capsule- and nerve-sparing cystectomy in organ-confined bladder cancer:preliminary results.World J Surg,2005,29(10):1277-1281.
19.Kubin M,Wagner G,and Fugl-Meyer AR:Epidemiology of erectile dysfunction.Int J Impot Res,2003,15(1):63-71.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |